Arcus Biosciences price to free cash flow RCUS

Market value divided by free cash flow over the last twelve months, since 2020.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 3.3×; May 2023
6-year median: 8.8×
6-year range: 2.8× to 189×
Peer median: 9.6×

Arcus Biosciences' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2023, at 3.3×.

On the days it had one over the last 6 years, its median was 8.8×, from 2.8× in Mar 2023 to 189× in Sep 2021.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	3.3×	2.8×	3.9×
2022	3.5×	3.1×	6.0×
2021	181×	13.4×	189×
2020	11.2×	8.8×	13.9×

Against its peers

Companies in Drug Manufacturers - General nearest Arcus Biosciences' size, closest first, today.

Company	Price to free cash flow
RCUSArcus Biosciences	n/m
PBHPrestige Consumer Healthcare	9.6×
HRMYHarmony Biosciences	n/m
NRIXNurix Therapeutics	7.5×
ANIPANI Pharmaceuticals	9.6×
PAHCPhibro Animal Health	160×
OGNOrganon	6.4×
LQDALiquidia	25.3×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	8.1×
ARQTArcutis Biotherapeutics	100×
Peer median	9.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Arcus Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.